What is TNYA's current stock price?

TNYA (Tenaya Therapeutics, Inc.) is currently trading at $0.77 with a market cap of $128.7M.

What sector is Tenaya Therapeutics, Inc. in?

Tenaya Therapeutics, Inc. (TNYA) operates in the Healthcare sector, specifically in the Biotechnology industry.

Is TNYA a good stock to buy?

Analysts have a Buy consensus on TNYA with a price target of $2.33. Check our detailed analysis for valuation, financials, and insider activity.

InvestLog

TNYA Tenaya Therapeutics, Inc.

Healthcare

$0.77-2.22%ClosedMarket Cap: $128.7M

As of 2026-05-25

Valuation

View Details

P/E (TTM)

—

PEG

—

P/B

1.11

P/S

572.01

EV/EBITDA

-0.75

DCF Value

$0.57

FCF Yield

-50.2%

Div Yield

0.0%

Margins & Returns

Gross Margin

144.9%

Operating Margin

-38159.1%

Net Margin

-36891.1%

ROE

-80.6%

ROA

-61.5%

ROIC

-70.7%

Financials

View All

Period	Revenue	Net Income	EPS
Q1 null	$225.0K	$-19.3M	$—
Q4 null	$0.00	$-20.2M	$—
FY null	$0.00	$-90.6M	$—
Q3 null	$0.00	$-20.3M	$—

Analyst Ratings

View All

Consensus

Buy

Target (Consensus)

$2.33

Target (Median)

$2.00

Target Range

$2.00 - $3.00

2 Strong Buy6 Buy0 Hold0 Sell0 Strong Sell

Chardan CapitalBuy

2026-03-12

Canaccord GenuityBuy

2025-12-18

Chardan CapitalBuy

2025-12-12

HC Wainwright & Co.Buy

2025-12-12

Chardan CapitalBuy

2025-11-10

Trading Activity

Insider Trades

View All

Tingley Whittemoreofficer: Chief Medical Officer

SellTue May 19

Higa Tomohiroofficer: SVP, Finance

SellTue May 19

Ali Farazdirector, officer: Chief Executive Officer

SellTue May 19

COLUMN GROUP III GP, LP10 percent owner

SellThu Feb 26

COLUMN GROUP III GP, LP10 percent owner

SellThu Feb 26

Company Info

Sector

Healthcare

Industry

Biotechnology

Country

Exchange

—

Beta

2.77

Tenaya Therapeutics, Inc., a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through cellular regeneration, gene therapy, and precision medicine platforms. The company is developing TN-201, an adeno-associated virus (AAV)-based gene therapy to address genetic hypertrophic cardiomyopathy (gHCM) caused by haploinsufficient myosin binding protein C3 (MYBPC3) gene mutations; and TN-301, a small molecule inhibitor of histone deacetylase 6 (HDAC6i) for use in heart failure with preserved ejection fraction (HFpEF) and genetic dilated cardiomyopathy (gDCM). It is also developing TN-401, an AAV-based gene therapy that addresses genetic arrhythmogenic right ventricular cardiomyopathy (gARVC) caused by plakophilin 2 (PKP2) gene mutations; an AAV-based gene therapy designed to deliver the dwarf open reading frame (DWORF) gene in the heart for DCM; and Reprogramming program, an AAV-based approach for cardiac regeneration to replace heart cells lost in patients experiencing heart failure due to prior myocardial infarction. The company was incorporated in 2016 and is headquartered in South San Francisco, California.

Peers